Status:
UNKNOWN
Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)
Lead Sponsor:
Poitiers University Hospital
Conditions:
Chronic Consumption of Cannabis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Cannabinoide Hyperemesis Syndrom (CHS) is defined as a recurrent syndrome of intractable vomiting that occurs in chronic cannabis consumers. The diagnosis is linked to clinical criteria only. The ...
Eligibility Criteria
Inclusion
- Subjects without protection by a legal regime (guardianship, trusteeship)
- Subjects affiliated to an appropriate social security system
- Subjects must sign an informed consent form
- Inclusion Criteria for Group 1:
- \- Subjects must have the CHS diagnosis confirmed
- Inclusion Criteria for Group 2:
- \- Subjects must be chronic cannabis consumers and never had CHS
Exclusion
- Subjects must not have addictive comorbidities or psychoactive substance abuse (except alcohol and tabacco)
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04836611
Start Date
July 1 2021
End Date
June 30 2023
Last Update
October 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Poitiers, France, 86000